UBS Group’s Turn Therapeutics TTRX Stock Holding History

UBS Group’s Portfolio TTRX Stock Details TTRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5K	Buy	2,263 +1,863	+466%	+$8.65K	﹤0.01%	8270
2026 Q1	$1.28K	Buy	+400	New	+$1.56K	﹤0.01%	9562

Other funds holding TTRX

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return

UBS Group's TTRX Position: Q2 2026 in Review

UBS Group increased its Turn Therapeutics (TTRX) stake by 466% in Q2 2026, buying an estimated $8.65K and bringing the position to 2,263 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #8270.

UBS Group first reported a position in TTRX in Q1 2026 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

UBS Group held 2,263 shares of Turn Therapeutics worth $16.5K as of Q2 2026.
UBS Group bought 1,863 Turn Therapeutics shares in Q2 2026, an estimated $8.65K.
Turn Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8270 holding.
UBS Group first reported a position in Turn Therapeutics in Q1 2026 and has held it in 2 quarters since.
29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.